Recently, the Multicenter Retrospective Cohort of Japanese Patients with Myositis-Associated ILD (JAMI) Investigators reported a matrix model for risk prediction using CRP and KL-6 combined with anti-MDA5, which might be useful for predicting prognosis in patients with PM/DM-ILD (16). This evidence concerns the gene CRP and dermatomyositis.